@stellanewslife STELLANEWS.LIFE

STELLANEWS.LIFE posts on X about japan, core, growth, $4507t the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

Engagements: [-----] #

[--] Week [------] +56,614%
[--] Month [------] +213%
[--] Months [------] +182%
[--] Year [------] +1,054%

Mentions: [--] #

[--] Week [--] +944%
[--] Month [---] +40%
[--] Months [---] +93%
[--] Year [---] +525%

Followers: [-----] #

[--] Week [-----] +1.20%
[--] Month [-----] +1.50%
[--] Months [-----] +26%
[--] Year [-----] +38%

CreatorRank: [---------] #

Social Influence

Social category influence stocks 26.13% countries 11.71% currencies 6.31% finance 4.5% travel destinations 2.7% exchanges 2.7% cryptocurrencies 0.9%

Social topic influence japan 7.21%, core 6.31%, growth 6.31%, $4507t 6.31%, strong 4.5%, sanofi #31, ai 3.6%, $abbv #10, regeneron #16, novo 3.6%

Top accounts mentioned or mentioned by @prevononet @hifukonews

Top assets mentioned Sanofi (SNY) AbbVie Inc (ABBV) Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AstraZeneca PLC (AZN) The 99% Community (99) Novartis AG (NVS) Gilead Sciences, Inc. (GILD) Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)

Top Social Posts

Top posts by engagements in the last [--] hours

"SNS AI http://STELLANEWS.LIFE http://STELLANEWS.LIFE"
X Link 2025-07-29T13:14Z [----] followers, [----] engagements

"C5gefurulimab3 gMGC5gefurulimab3PREVAIL ✔ AChRgMG26MG-ADL ✔ PFS ✔ ✔ UltomirisSoliris ✔ AI★★★★☆ C5 # #gefurulimab #gMG # #C5 # # #3 #Ultomiris #Soliris # #MGFA #AANEM"
X Link 2025-11-04T00:57Z [----] followers, [---] engagements

"0.1👁💧 [---] 🔹 🔹 🔹 3MRD-1 📖 [--------] # #Upneeq # # # # # #"
X Link 2025-12-31T16:15Z [----] followers, [---] engagements

"Teva and Royalty Pharma announce up to $500M funding for antiIL-15 antibody TEV-408 in vitiligo 💡 The agreement supports late-stage development of TEV-408 including: 💵 $75M co-funding for a Phase 2b trial (starting 2026) 💵 Up to $425M optional co-funding for Phase [--] based on trial results TEV-408 a human monoclonal antibody targeting IL-15 is in Phase 1b for vitiligo and Phase 2a for celiac disease. If approved Teva will pay milestones and royalties to Royalty Pharma. 🔗 Read more: #Teva #RoyaltyPharma #TEV408 #IL15 #Vitiligo #AutoimmuneDiseases #Biopharma #ClinicalTrials #Funding"
X Link 2026-01-13T20:16Z [----] followers, [--] engagements

"DLBCLPFS3 ✔ DLBCLPFS ✔ HR0.7495CI 0.600.92OS ✔ AbbVieGenmabCD3CD20epcoritamab3EPCORE DLBCL-1PFS OS # # #"
X Link 2026-01-21T21:07Z [----] followers, [---] engagements

"Epcoritamab improves PFS in Phase [--] EPCORE DLBCL-1 trial AbbVie: Epcoritamab shows first statistically significant PFS benefit over chemoimmunotherapy in R/R DLBCL AbbVie and Genmab announced topline results from the Phase [--] EPCORE DLBCL-1 trial evaluating subcutaneous epcoritamab a CD3xCD20 bispecific antibody in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Key findings: Progression-free survival (PFS) improved significantly vs investigators choice chemoimmunotherapy (HR = 0.74; 95% CI 0.600.92) Overall survival (OS) did not reach statistical significance (HR"
X Link 2026-01-21T21:08Z [----] followers, [---] engagements

"202633 ✔ 21085.434820.3 ✔ ✔ [-------------------] [--] # # #"
X Link 2026-02-11T10:47Z [----] followers, [---] engagements

"20263 3IFRS Santen Pharmaceutical Co. Ltd. Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March [--] [----] (IFRS) For the nine months ended December [--] [----] revenue decreased [---] year on year to JPY [-----] billion while core operating profit declined [----] to JPY [----] billion. Operating profit under full IFRS fell [----] to JPY [----] billion. In Japan results were affected by NHI price revisions and the impact of policy changes related to long-listed products. China remained broadly flat excluding foreign exchange effects despite inventory adjustments. Asia (excluding"
X Link 2026-02-11T10:47Z [----] followers, [--] engagements

"202633 ✔ 347718.61094408.5 ✔ ✔ [----------------------] [--] [-------] # # #"
X Link 2026-02-11T10:49Z [----] followers, [---] engagements

"20263 3IFRS Sumitomo Pharma Co. Ltd. Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March [--] [----] (IFRS) For the nine months ended December [--] [----] revenue increased [----] year on year to JPY [-----] billion. Core operating profit rose [-----] to JPY [-----] billion while operating profit reached JPY [-----] billion. Growth was primarily driven by North America where relugolix ORGOVYX for advanced prostate cancer and vibegron GEMTESA for overactive bladder expanded sales. A sales milestone related to ORGOVYX was also recorded. In Japan revenue declined due to the loss"
X Link 2026-02-11T10:49Z [----] followers, [---] engagements

"loncastuximab tesirine1/2 r/r DLBCL ✔ CD19loncastuximab tesirine1/2 ✔ Br/r DLBCL ✔ [--] CD19loncastuximab tesirineB1/2MT-2111-A-101 [---] DLBCL2 #DLBCL # #"
X Link 2026-02-11T11:18Z [----] followers, [---] engagements

"loncastuximab tesirine1/2DLBCL Tanabe Pharma: Phase 1/2 Study of Loncastuximab Tesirine in Japan Meets Primary Endpoint in r/r DLBCL Tanabe Pharma announced that a domestic Phase 1/2 bridging study of loncastuximab tesirine met its primary endpoint in patients with relapsed or refractory diffuse large B-cell lymphoma r/r DLBCL. The open-label single-arm multicenter study MT-2111-A-101 enrolled [--] patients in Japan. The primary endpoint was overall response rate assessed by independent central review. According to the company the study achieved this endpoint. The safety profile was reported to"
X Link 2026-02-11T11:19Z [----] followers, [---] engagements

"ATPCTLA-4ROSE12 🔹 CTLA-4ROSE12JITC 🔹 ATPTreg 🔹 [--] Switch-IgCTLA-4ROSE12Journal for ImmunoTherapy of Cancer ROSE12ATPCTLA-4ADCCTTreg [--] # #ROSE12 #CTLA4 # #SwitchIg https://twitter.com/i/web/status/2021551275926786483 https://twitter.com/i/web/status/2021551275926786483"
X Link 2026-02-11T11:45Z [----] followers, [---] engagements

"Regeneron2025143Dupixent 🔹 2025143+1% 🔹 438.8+3% 🔹 Dupixent178+26% Regeneron20254DupixentEYLEA HDEYLEA [----] #Regeneron # # #Dupixent #EYLEA https://twitter.com/i/web/status/2021579449884660097 https://twitter.com/i/web/status/2021579449884660097"
X Link 2026-02-11T13:37Z [----] followers, [----] engagements

"Regeneron Reports Fourth Quarter and Full Year [----] Financial and Operating Results Regeneron reported full-year [----] revenue of $14.3 billion (+1% YoY) and fourth-quarter revenue of $3.9 billion (+3% YoY). Global net sales of Dupixent reached $17.8 billion for the year (+26%) while EYLEA HD continued to grow in the U.S. The company also provided [----] financial guidance and outlined multiple regulatory milestones across ophthalmology immunology oncology and rare diseases."
X Link 2026-02-11T13:38Z [----] followers, [---] engagements

"Astellas2025310.2%48.6% 🔹 1601310.2% 🔹 442148.6% 🔹 331648.7% 🔹 EPS185.2048.6% [--------] PADCEVIZERVAYVYLOYVEOZAHXTANDI SMT # # # #StrategicBrands https://twitter.com/i/web/status/2021582065448473008 https://twitter.com/i/web/status/2021582065448473008"
X Link 2026-02-11T13:48Z [----] followers, [--] engagements

"Novo Nordisk 🔹 [-------] 🔹 Novo Nordisk A/S Novo Nordisk2018Thomas Rantzau22 Tanja Villumsen #NovoNordisk # # # https://twitter.com/i/web/status/2021584315218600385 https://twitter.com/i/web/status/2021584315218600385"
X Link 2026-02-11T13:57Z [----] followers, [---] engagements

"New employee representative on the Board of Directors of Novo Nordisk A/S Date: January [--] [----] 🔹 Company announcement No. [--] / 2026Novo Nordisk announced that Thomas Rantzau employee representative on the Board since [----] has decided to step down after [--] years with the company.His alternate Tanja Villumsen has joined the Board of Directors as employee representative with immediate effect.#NovoNordisk #CorporateGovernance #BoardOfDirectors #HealthcareIndustry https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.htmlid=916480"
X Link 2026-02-11T13:57Z [----] followers, [--] engagements

"Novo Nordisk2025DKK 3090CER10 🔹 DKK [-----] billion6CER10 🔹 DKK [-----] billion1CER6 🔹 DKK [-----] billion1 🔹 EPSDKK [------] DKK [-----] billion7CER10 26CER31 GLP-1Wegovy pillsemaglutide 25mg20261512350000 2026CER513 2025DKK 7.95DKK [-----] DKK [---] #NovoNordisk # #GLP1 # # https://twitter.com/i/web/status/2021584771122712775 https://twitter.com/i/web/status/2021584771122712775"
X Link 2026-02-11T13:59Z [----] followers, [---] engagements

"Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK [-----] billion in [----] 📅 February [--] [----] (Company announcement No. [--] / 2026) Novo Nordisk reported [----] net sales of DKK [-----] billion (+6% reported +10% CER). Operating profit reached DKK [-----] billion (1% reported +6% CER) while net profit was DKK [-----] billion and diluted EPS DKK [-----]. Obesity care grew 26% (31% CER) and GLP-1 diabetes sales increased 2% (6% CER). The company launched oral Wegovy in the U.S. in January [----] with weekly prescriptions reaching [-----] shortly after launch. For"
X Link 2026-02-11T13:59Z [----] followers, [--] engagements

"Amgen2025368EPS 🔹 2025368+10% 🔹 499+9% 🔹 GAAP EPS14.23+88% 🔹 Non-GAAP EPS21.84+10% Amgen20252351+10%181410 Repatha+36%EVENITY+34%TEZSPIRE+52%UPLIZNA+73%Enbrel33%XGEVA6% GAAP91+25%25.8% [--] [----] 📌 [------] 📌 GAAP EPS15.4516.94 📌 Non-GAAP EPS21.6023.00 #Amgen # # # # https://twitter.com/i/web/status/2021588938805113163 https://twitter.com/i/web/status/2021588938805113163"
X Link 2026-02-11T14:15Z [----] followers, [--] engagements

"AMGEN REPORTS FOURTH QUARTER AND FULL YEAR [----] FINANCIAL RESULTS 📅 February [--] [----] Amgen reported strong [----] financial performance with full-year revenue increasing 10% year-over-year to $36.8 billion and GAAP EPS rising 88% to $14.23. Fourth-quarter revenue reached $9.9 billion (+9%) supported by 7% product sales growth driven by 10% volume growth. Key growth drivers included: Repatha: $3.0B FY sales (+36%) EVENITY: $2.1B (+34%) TEZSPIRE: $1.48B (+52%) UPLIZNA: $655M (+73%) For [----] Amgen expects revenue of $37.0$38.4 billion and non-GAAP EPS of $21.60$23.00. The company also generated"
X Link 2026-02-11T14:15Z [----] followers, [--] engagements

"Gilead2025294 Biktarvy143 Gilead Sciences20254 📷 2025294+2% 📷 289+1% 📷 Veklury280+4% 📷 EPS6.780.38 📷 Non-GAAP EPS8.154.62 HIVBiktarvy143+7% Descovy28+31% COVID-19Veklury9.11-49% 📷 [----] [------] EPS6.757.15 Non-GAAP EPS8.458.85 HIV2026 #Gilead # #HIV # # https://twitter.com/i/web/status/2021596208419189011 https://twitter.com/i/web/status/2021596208419189011"
X Link 2026-02-11T14:44Z [----] followers, [--] engagements

"📷 📷 📷 # # #"
X Link 2026-02-11T14:46Z [----] followers, [---] engagements

"Lilly reports fourth-quarter [----] financial results and provides [----] guidance Eli Lilly and Company reported a 43% year-over-year increase in Q4 [----] revenue to $19.3 billion primarily driven by volume growth of tirzepatide marketed as Mounjaro for type [--] diabetes and Zepbound for obesity. Key highlights: Q4 [----] EPS increased to $7.39 (reported) and $7.54 (non-GAAP) both including $0.52 of acquired IPR&D charges. Mounjaro revenue reached $7.4 billion (+110%) while Zepbound generated $4.2 billion in the U.S. (+122%). [----] guidance projects revenue of $80$83 billion and non-GAAP EPS of"
X Link 2026-02-11T14:46Z [----] followers, [--] engagements

"✔ ✔ ✔ # # #"
X Link 2026-02-11T15:18Z [----] followers, [---] engagements

"AstraZeneca results: FY and Q4 [----] AstraZeneca reported FY2025 total revenue of $58739 million up 8% at constant exchange rates with growth across Oncology CVRM Respiratory & Immunology and Rare Disease. Core EPS increased 11% to $9.16. The company announced [--] positive Phase [--] readouts and [--] approvals in major regions over the past twelve months. More than [---] Phase [--] trials are ongoing with over [--] additional Phase [--] readouts expected in [----]. Guidance for FY2026 indicates: Total Revenue expected to increase by a mid-to-high single-digit percentage at CER. Core EPS expected to increase"
X Link 2026-02-11T15:18Z [----] followers, [--] engagements

"2025436 ✔ [--------------] ✔ [------] ✔ [-----] 20254202543626009.91EPS7.8315.0 413.34232.2202.5 236.62025103COAST 2SHORE3 20261EPS # # #"
X Link 2026-02-11T15:31Z [----] followers, [---] engagements

"Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in [----] [--------] Sanofi reported FY2025 net sales of [-----] million up 9.9% at constant exchange rates. Business EPS reached [----] increasing 15.0% at CER while IFRS EPS was [----] for the full year. In Q4 [----] sales grew 13.3% at CER. Dupixent (dupilumab) sales increased 32.2% to [---] billion while vaccines sales declined 2.5% to [---] billion. Business EPS for the quarter was [----] up 26.7% at CER; IFRS EPS was [-----]. Pipeline updates included: Ten regulatory approvals across immunology and rare diseases."
X Link 2026-02-11T15:31Z [----] followers, [---] engagements

"2025482 ✔ [-----------] ✔ Non-GAAP EPS6.15IPRD ✔ [----------] [-------------] [----------] GAAPEPS3.46Non-GAAP EPS6.15IPRD1.404Non-GAAP EPS1.26 2026460475Non-GAAP EPS6.056.3510.6317 [----] # # #"
X Link 2026-02-11T15:35Z [----] followers, [--] engagements

"Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for [----] [-----] Bristol Myers Squibb reported full-year [----] revenues of $48.2 billion relatively flat year over year (1% excluding FX). Growth Portfolio revenues increased 17% to $26.4 billion. Fourth quarter revenues were $12.5 billion up 1% year over year. Growth Portfolio revenues reached $7.4 billion (+16%) driven by the immuno-oncology portfolio Camzyos Breyanzi and Reblozyl. Legacy Portfolio revenues declined 15% reflecting generic impact and higher U.S. government rebates. Full-year GAAP EPS was $3.46 and"
X Link 2026-02-11T15:35Z [----] followers, [--] engagements

"2025650 [---] ✔ [--------] ✔ QLEX3177 ✔ 2026Non-GAAP EPS5.005.15 [-------------------] QLEX317714217.5993952 GAAP EPS7.28Non-GAAP EPS8.982026655670Non-GAAP EPS5.005.1536.513.65 [--------------] # # #"
X Link 2026-02-11T15:54Z [----] followers, [--] engagements

"Merck & Co. Inc. Rahway N.J. USA Announces Fourth-Quarter and Full-Year [----] Financial Results; Highlights Progress Advancing Broad Diverse Pipeline [-----] Merck reported full-year [----] worldwide sales of $65.0 billion up 1% (2% ex-FX). Fourth-quarter sales were $16.4 billion increasing 5%. KEYTRUDA/KEYTRUDA QLEX (pembrolizumab) generated $31.7 billion in [----] up 7%. WINREVAIR (sotatercept) sales reached $1.4 billion and CAPVAXIVE recorded $759 million. GARDASIL/GARDASIL [--] sales declined 39% to $5.2 billion primarily reflecting lower demand in China. Full-year GAAP EPS was $7.28 and non-GAAP"
X Link 2026-02-11T15:55Z [----] followers, [--] engagements

"2025545 [--] ✔ [--------] ✔ 40.1EPS8.98 ✔ [------] 20255453200821889001440.1EPS8.9817 [-----] 20253FDA [------] # # #"
X Link 2026-02-11T15:57Z [----] followers, [---] engagements

"Novartis delivered high single-digit sales growth achieved 40% core margin and further advanced the pipeline in [----] [----] Novartis reported FY2025 net sales of $54.5 billion up 8% at constant currencies. Core operating income increased 14% (cc) reaching a core margin of 40.1%. Core EPS rose 17% (cc) to $8.98. Growth was driven by priority brands including Kisqali (+57% cc) Kesimpta (+36% cc) Pluvicto (+42% cc) Scemblix (+85% cc) and Cosentyx (+8% cc). In Q4 net sales were $13.3 billion (1% cc) impacted by U.S. generic erosion and revenue deduction adjustments. Core operating income increased"
X Link 2026-02-11T15:57Z [----] followers, [--] engagements

"2025942 [--------] ✔ [----------] ✔ EPS11.03EPS10.79 ✔ [--------] 2025494193006.05.3 424564009.14EPS2.10EPS2.4610.10 Innovative Medicine6045.3MedTech3385.4 202610001010EPS11.4311.63 # # #"
X Link 2026-02-11T15:59Z [----] followers, [--] engagements

"Johnson & Johnson reports Q4 and Full-Year [----] results [-----] Johnson & Johnson reported full-year [----] sales of $94.2 billion up 6.0% year over year with operational growth of 5.3%. Diluted EPS was $11.03 and adjusted EPS was $10.79. Fourth-quarter sales were $24.6 billion increasing 9.1%. Q4 EPS was $2.10 and adjusted EPS was $2.46 both including a $(0.10) impact related to the acquisition of Halda Therapeutics. Innovative Medicine delivered $60.4 billion in full-year sales (+5.3% operational) driven by DARZALEX CARVYKTI ERLEADA and RYBREVANT/LAZCLUZE partially offset by STELARA erosion."
X Link 2026-02-11T16:00Z [----] followers, [--] engagements

"2025611.6 2026EPS14.3714.57 ✔ [--------------] ✔ EPS10.00IPR&D12.76 ✔ 2026EPS14.3714.57 2025461160008.68.5GAAPEPS2.36EPS10.00IPR&D12.76 30414.017562008340045400049.5 107670019.63769003621006655001.54860006.1 4166180010.0EPS2.71 2026EPS14.3714.57IPR&D #AbbVie #"
X Link 2026-02-11T16:02Z [----] followers, [---] engagements

"AbbVie Reports Full-Year and Fourth-Quarter [----] Financial Results reported full-year [----] net revenues of $61.160 billion up 8.6% reported (8.5% operational). GAAP diluted EPS was $2.36 and adjusted diluted EPS was $10.00 including an unfavorable $2.76 per share impact from acquired IPR&D and milestones expense.Immunology delivered $30.406 billion (+14.0%) driven by Skyrizi ($17.562 billion) and Rinvoq ($8.304 billion) partially offset by Humira ($4.540 billion -49.5%). Neuroscience grew 19.6% to $10.767 billion while Oncology increased 1.5% to $6.655 billion. Aesthetics declined 6.1% to"
X Link 2026-02-11T16:02Z [----] followers, [---] engagements

"20257 🔹 2025615CER7 🔹 [--] 🔹 EPS11IFRS58 🔹 2026EPS 20256151600CER7CHF248 47669009A [--------] 218330013EPS19.4611IFRS137990058 [-------] 2026EPS #Roche # #"
X Link 2026-02-11T16:11Z [----] followers, [--] engagements

"Roche reports strong [----] results with 7% sales growth [----] Roche reported [----] group sales of CHF [-----] million up 7% at constant exchange rates (2% in CHF). Core operating profit increased 13% and core EPS rose 11% to CHF [-----]. IFRS net income climbed 58% to CHF [-----] million. Pharmaceuticals sales grew 9% to CHF [-----] million driven by Phesgo Xolair Ocrevus Hemlibra and Vabysmo. Diagnostics sales increased 2% to CHF [-----] million supported by pathology and molecular testing demand. For [----] Roche expects mid single-digit sales growth and high single-digit core EPS growth (CER). The Board"
X Link 2026-02-11T16:11Z [----] followers, [--] engagements

"FDALEQEMBI IQLIK1 PDUFA524 🔹 FDA1500mgsBLA 🔹 PDUFA2026524 🔹 IV BiogenALEQEMBI IQLIK1sBLAFDA IV1500mg 3Clarity ADOLE1IV IV2 360mg20258 #FDA #LEQEMBI # #"
X Link 2026-02-11T16:25Z [----] followers, [--] engagements

"FDA Accepts sBLA for Weekly Subcutaneous LEQEMBI IQLIK as Initial Therapy FDA has accepted a supplemental BLA for weekly (500mg) subcutaneous dosing of lecanemab (LEQEMBI IQLIK) as initial therapy for early Alzheimers disease and granted Priority Review. The PDUFA action date is May [--] [----]. The filing is supported by a sub-study from the Phase [--] Clarity AD open-label extension reporting comparable exposure and similar clinical and biomarker effects versus biweekly IV dosing. Safety was described as consistent with IV administration with systemic injection-related reactions occurring in less"
X Link 2026-02-11T16:26Z [----] followers, [--] engagements

"HenliusPD-1serplulimab 🔹 🔹 [--] 🔹 [----] 🔹 [----] Shanghai Henlius BiotechPD-1serplulimab ES-SCLC22026 [-------------] # #Henlius #PD1 #"
X Link 2026-02-11T16:28Z [----] followers, [---] engagements

"Eisai Partners with Shanghai Henlius on Anti-PD-1 Antibody Serplulimab in Japan and Shanghai Henlius announced a license agreement granting Eisai exclusive commercialization rights to the anti-PD-1 antibody serplulimab in Japan along with joint development and manufacturing as Japan a Phase [--] bridging study in extensive-stage small cell lung cancer is ongoing and a regulatory filing is planned within fiscal year 2026.The deal includes an upfront payment of $75 million regulatory milestones of up to $80.01 million sales milestones of up to $233.30 million and double-digit percentage royalties"
X Link 2026-02-11T16:29Z [----] followers, [--] engagements

"NMPA 🔹 BLA 🔹 1500mg 🔹 🔹 [-----] BiogenBLANMPA 20261211500mg 250mg2115NMPA # # #NMPA #"
X Link 2026-02-11T16:30Z [----] followers, [---] engagements

"YCANTH0.71 🔹 [------] 🔹 [-----] 🔹 [--] YCANTH0.71 20259192025111214995.600.45mL [-----] [--] # # #YCANTH #"
X Link 2026-02-11T16:32Z [----] followers, [--] engagements

"Shionogi Group Launches YCANTH 0.71% Topical Solution in Japan for Molluscum Contagiosum announced that its group company Torii Pharmaceutical has launched YCANTH topical solution 0.71% (cantharidin) in Japan for the treatment of molluscum contagiosum.The product was approved in September [----] and listed under the NHI price system in November [----]. It is indicated for patients aged [--] years and older applied every three weeks and washed off after [----] hours.According to the company a Japan Phase [--] clinical program met the primary endpoint versus vehicle with safety and tolerability"
X Link 2026-02-11T16:32Z [----] followers, [---] engagements

"SCS575DRG73 🔹 SCS575 🔹 DRG573834 🔹 MRIFDA NANS 2026SCS575 Proclaim DRG834573 Proclaim SCSEterna SCSProclaim DRGMRIFDA # #SCS #DRG # #"
X Link 2026-02-11T16:34Z [----] followers, [--] engagements

"Abbott Reports 75% Reduction in Pain-Related Healthcare Visits at [--] Years with SCS SCS575 Abbott presented five-year real-world data at NANS [----] showing an average 75% reduction in pain-related healthcare visits among patients treated with its spinal cord stimulation (SCS) systems. For its Proclaim DRG system a retrospective study of [---] patients reported a 73% average reduction in pain-related healthcare utilization at five years. The company also announced FDA approval allowing prone-position MRI access for certain neuromodulation systems potentially expanding imaging options requiring"
X Link 2026-02-11T16:34Z [----] followers, [--] engagements

"RT @prevononet: [--------------] # #"
X Link 2026-02-12T00:20Z [----] followers, [--] engagements

"RT @prevononet: NHS HPV254935 PREVONO # # https://prevono.net/world/489/ https://prevono.net/world/489/"
X Link 2026-02-12T00:20Z [----] followers, [--] engagements

"RT @prevononet: Vol.1 PREVONO # # https://prevono.net/interview/383/ https://prevono.net/interview/383/"
X Link 2026-02-12T00:20Z [----] followers, [--] engagements

"RT @prevononet: PREVONO"
X Link 2026-02-12T00:21Z [----] followers, [--] engagements

"RT @hifuko_news:"
X Link 2026-02-12T06:52Z [----] followers, [--] engagements

"8mgRVO364 ✔ RVO3QUASAR64 ✔ wAMDDME13bELARA ✔ [--] Angiogenesis 20268mgretinal vein occlusionRVO3QUASAR6436 wAMDDME413bELARA [--] # # #"
X Link 2026-02-12T14:02Z [----] followers, [---] engagements

"8mgRVO364ELARA1 Regeneron to Present Final 64-Week Phase [--] QUASAR Results in RVO and Primary Data from Monthly Dosing ELARA Trial of Aflibercept [--] mghttps://stellanews.life/technology/8814/Regeneron announced upcoming presentations at the Angiogenesis Angiogenesis Exudation and Degeneration [----] annual meeting highlighting new data for aflibercept injection [--] mg in retinal diseases.Planned disclosures include final 64-week results from the Phase [--] QUASAR trial in retinal vein occlusion RVO which previously met its primary endpoint at [--] weeks as well as primary results from the Phase 3b ELARA"
X Link 2026-02-12T14:02Z [----] followers, [--] engagements

"AAAAI [------] ✔ [--] ✔ Fel d 1Bet v [--] ✔ IgE [--] # # #"
X Link 2026-02-12T14:15Z [----] followers, [---] engagements

"AAAAI [------] Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI [----] Regeneron announced [--] abstracts in immunology and inflammation at AAAAI [----] including first Phase [--] ocular allergen-challenge data for investigational antibody cocktails targeting Fel d [--] and Bet v [--]. New analyses of dupilumab in pediatric atopic dermatitis and asthma real-world settings are also scheduled. The presentations include late-breaking Phase [--] AIMS data in allergic fungal rhinosinusitis and outline next-step registration-oriented trials planned this year. AI impact ratingreference only:"
X Link 2026-02-12T14:16Z [----] followers, [--] engagements

"32025173 ✔ 20251734% ✔ 3035% ✔ GAAP EPS2.93 AUSTEDOAJOVYUZEDYQ410 anti-TL1Aanti-IL-15 #Teva # # # https://twitter.com/i/web/status/2022008714082005258 https://twitter.com/i/web/status/2022008714082005258"
X Link 2026-02-12T18:03Z [----] followers, [---] engagements

"NYSE ✔ 202622NYSE ✔ NYSELSE ✔ AZN [---------] #AstraZeneca #NYSE # #"
X Link 2026-02-12T19:44Z [----] followers, [--] engagements

"AstraZeneca begins trading on the New York Stock Exchange AstraZeneca has begun trading its ordinary shares on the NYSE under the ticker AZN aligning its listing structure across New York London and Stockholm. The move provides broader access to U.S. capital markets while maintaining inclusion in the FTSE [---] and OMX Stockholm [--] indices. The company highlighted continued pipeline momentum and reaffirmed its ambition to reach $80 billion in annual revenue by [----] alongside launching [--] new medicines. #CapitalMarkets #Biopharma #AZN #CorporateNews"
X Link 2026-02-12T19:44Z [----] followers, [--] engagements

"10 ✔ [------] ✔ [--] ✔ [------] #Sanofi # # #"
X Link 2026-02-12T20:42Z [----] followers, [---] engagements

"Sanofi signs mandate for up to [--] billion share buyback program in [----] Sanofi has entered into a mandate agreement with an investment services provider to execute a share buyback program of up to [--] billion in [----]. The repurchases are planned to take place between February [--] and December [--] [----] subject to renewal of the Boards authorization at the April [--] [----] shareholders meeting. The initiative aligns with the companys previously announced capital allocation strategy for [----]. #CapitalAllocation #Pharma #CorporateFinance #SAN"
X Link 2026-02-12T20:42Z [----] followers, [--] engagements

"BMSJ&JFXIa ✔ Change the Target. Change Whats Possible. ✔ [--] ✔ FXIa FXIa #BMS #JohnsonAndJohnson #FXIa # #"
X Link 2026-02-15T01:57Z [----] followers, [--] engagements

"Bristol Myers Squibb and Johnson & Johnson launched the clinician-focused campaign Change the Target. Change Whats Possible. to highlight unmet needs in cardiovascular and thromboembolic care. Cardiovascular and thromboembolic diseases account for nearly [--] million deaths annually in the U.S. Despite available therapies 40% of atrial fibrillation patients remain untreated or undertreated and about 25% of strokes are recurrent. The campaign emphasizes the emerging potential of factor XIa (FXIa) inhibition which may help reduce thrombosis while preserving healthy clotting and minimizing bleeding"
X Link 2026-02-15T01:57Z [----] followers, [--] engagements

"BMSGK ✔ ✔ CD19CAR-TBreyanzi ✔ BreyanziTCAR-TB #BMS #Breyanzi #CART # #WorldCancerDay"
X Link 2026-02-15T02:00Z [----] followers, [--] engagements

"Bristol Myers Squibb partnered with former U.S. Mens National Team goalkeeper Kasey Keller to share his personal journey with non-Hodgkin lymphoma and treatment with Breyanzi (lisocabtagene maraleucel) a CD19-directed CAR T cell therapy. Breyanzi is a personalized one-time infusion therapy made from a patients own T cells and is FDA-approved across five indications the broadest label among CD19 CAR T therapies. Keller is speaking publicly for the first time to raise awareness about treatment options and encourage patients to engage in informed discussions with their healthcare teams."
X Link 2026-02-15T02:00Z [----] followers, [--] engagements

"ADHDFDA ✔ FDA ✔ [--] ✔ PDUFA2026724 ADHD11NDAFDAPDUFA2026724 [--] #ADHD # #"
X Link 2026-02-15T04:11Z [----] followers, [--] engagements

"CART BP pro ✔ [--] ✔ PPG ✔ Sky Labs Sky LabsCART BP pro [--] Scientific Reports # # #"
X Link 2026-02-15T04:16Z [----] followers, [--] engagements

"Gilead Sciences Announces Fourth Quarter and Full Year [----] Financial Results FOSTER CITY Calif. February [--] [----] Gilead Sciences (Nasdaq: GILD) reported full year [----] revenues of $29.4 billion up 2% year over year. Product sales excluding Veklury rose 4% to $28.0 billion. Full year HIV sales increased 6% to $20.8 billion led by: Biktarvy: $14.3 billion (+7%) Descovy: $2.8 billion (+31%) Fourth quarter [----] revenues were $7.9 billion (+5%) with diluted EPS of $1.74 (non-GAAP $1.86). For [----] Gilead expects product sales of $29.630.0 billion and non-GAAP EPS of $8.458.85. #Gilead #Earnings"
X Link 2026-02-11T14:44Z [----] followers, [--] engagements

"HER2 ✔ HER2 ✔ 3DESTINY-Gastric04 ✔ HER2 # #HER2 #"
X Link 2026-02-12T14:38Z [----] followers, [---] engagements

"Dato-DXdFDA ✔ TNBC ✔ PDUFA202662 ✔ 3TROPION-Breast02OS TROP2 # # #"
X Link 2026-02-12T14:45Z [----] followers, [---] engagements

"CD37 ADC12 ✔ BFirst Patient In ✔ ✔ [---] DS3790CD37DXdDXd ADC12 # # #1"
X Link 2026-02-12T14:55Z [----] followers, [---] engagements

"ADHDFDAPDUFA2026724 Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD AI Impact EvaluationReference: ★★★★☆ *This is an experimental index and is a reference value whose accuracy is not guaranteed. #ADHD #OtsukaPharmaceutical #FDA #Centanafadine #PriorityReview #MentalHealth #Pharmaceuticals https://stellanews.life/technology/8843/ https://stellanews.life/technology/8843/"
X Link 2026-02-15T04:12Z [----] followers, [--] engagements

"BayerECR 2026MRIgadoquatrane3 ✔ gadoquatrane3 ✔ [----] mmol/kg60 ✔ MRIMRA Bayer20263ECR 2026MRIgadoquatrane3QUANTI [--] kg0.04 mmol0.1 mmol/kg60 2025EU #MRI # #Bayer # #ECR2026 #"
X Link 2026-02-15T10:46Z [----] followers, [--] engagements

"CEOBeln GarijoCEO ✔ CEO217 ✔ Beln Garijo429 ✔ Olivier CharmeilCEO R&D #Sanofi #CEO # #"
X Link 2026-02-15T01:47Z [----] followers, [--] engagements

"Bristol Myers Squibb announced it will serve as an inaugural partner in Life Science Cares national campaign Food is Health: Nourishing Communities Advancing Health. The initiative aims to invest $30 million and mobilize [-----] volunteer hours by [----] to address food insecurity and improve long-term health outcomes. BMS will contribute $5 million to support the effort. With over [--] million Americans experiencing food insecurity each year the campaign underscores growing evidence that access to nutritious food is essential to disease prevention treatment adherence and health equity."
X Link 2026-02-15T02:03Z [----] followers, [--] engagements

"Astellas Reports Financial Results for the First Nine Months of FY2025 Revenue: [------] billion (+10.2% YoY) 🔹 Core operating profit: [-----] billion (+48.6% YoY) 🔹 Core profit: [-----] billion (+48.7% YoY) 🔹 Core EPS: 185.20Astellas reported strong year-on-year growth for the first nine months of FY2025 driven by Strategic Brands including PADCEV IZERVAY VYLOY and VEOZAH as well as continued expansion of XTANDI.Cost optimization initiatives under SMT also contributed to the significant profit increase. https://twitter.com/i/web/status/2021582226488692850"
X Link 2026-02-11T13:48Z [----] followers, [--] engagements

"HER2DESTINY-Gastric04 ENHERTU (trastuzumab deruxtecan) approved in China for second-line HER2-positive gastric cancer based on DESTINY-Gastric04 Daiichi Sankyo announced that Chinas National Medical Products Administration (NMPA) approved ENHERTU an anti-HER2 antibody-drug conjugate for second-line treatment of HER2-positive unresectable advanced or recurrent gastric or gastroesophageal junction adenocarcinoma after prior trastuzumab-containing therapy. The approval is based on the global Phase [--] DESTINY-Gastric04 trial and was granted under Breakthrough Therapy Designation and Priority"
X Link 2026-02-12T14:39Z [----] followers, [---] engagements

"Dato-DXdTNBCFDATROPION-Breast02 FDA grants Priority Review for datopotamab deruxtecan in first-line TNBC based on TROPION-Breast02 Daiichi Sankyo announced that the U.S. FDA accepted a supplemental biologics license application for datopotamab deruxtecan a TROP2-directed antibody-drug conjugate as first-line treatment for unresectable or metastatic triple-negative breast cancer not eligible for PD-1/PD-L1 inhibitors. The application received Priority Review with a PDUFA target date of June [--] [----]. The filing is based on the global Phase [--] TROPION-Breast02 trial in which the company reported a"
X Link 2026-02-12T14:45Z [----] followers, [---] engagements

"CD37 ADCDS37901/2/BNHL420 Daiichi Sankyo initiates first patient dosing of DS3790 a CD37-targeted DXd ADC in global Phase 1/2 trial for relapsed/refractory B-cell NHL Daiichi Sankyo announced first patient dosing in a global Phase 1/2 study of DS3790 an antibody-drug conjugate targeting CD37 in relapsed or refractory B-cell non-Hodgkin lymphoma. The trial evaluates DS3790 as monotherapy and in combination with targeted therapies assessing safety including dose-limiting toxicities and preliminary efficacy endpoints such as ORR PFS and OS. Approximately [---] patients are planned for enrollment"
X Link 2026-02-12T14:55Z [----] followers, [---] engagements

"MIBCsNDA ✔ MIBC ✔ 3EV-303KEYNOTE-905 ✔ [--] PADCEVEFSOS # # #"
X Link 2026-02-12T17:09Z [----] followers, [---] engagements

"PADCEVKeytrudasNDAMIBCEV-303/KEYNOTE-905 Astellas submits sNDA in Japan for PADCEV (enfortumab vedotin) plus Keytruda (pembrolizumab) as perioperative therapy in cisplatin-ineligible MIBC Astellas announced the submission of a supplemental NDA in Japan for enfortumab vedotin plus pembrolizumab as perioperative treatment (neoadjuvant and adjuvant) for adults with muscle-invasive bladder cancer ineligible for cisplatin-based chemotherapy. The filing is based on the Phase [--] EV-303/KEYNOTE-905 trial. The company reported a 60% reduction in the risk of recurrence progression or death and a 50%"
X Link 2026-02-12T17:10Z [----] followers, [---] engagements

"3VMS ✔ 3STARLIGHT [--] ✔ 8VMS ✔ [--] [--] mg45 mg11410 # # #3"
X Link 2026-02-12T17:15Z [----] followers, [---] engagements

"3STARLIGHT 2VMS Astellas reports positive Phase [--] STARLIGHT [--] results in Japan for fezolinetant in vasomotor symptoms Astellas announced topline results from the randomized double-blind placebo-controlled Phase [--] STARLIGHT [--] study in Japan evaluating fezolinetant for vasomotor symptoms associated with menopause. In [---] participants once-daily [--] mg and [--] mg doses significantly reduced VMS frequency from baseline to Week [--] versus placebo meeting the primary endpoint. Serious adverse events were reported in fewer than 4% of participants. Detailed effect sizes and longer-term data are expected"
X Link 2026-02-12T17:15Z [----] followers, [---] engagements

"✔ Lupin ✔ ✔ [-----] # # #"
X Link 2026-02-12T17:20Z [----] followers, [---] engagements

"Lupin Astellas reaches settlement with Lupin in U.S. mirabegron patent litigation Astellas announced a settlement agreement with Lupin Limited and Lupin Pharmaceuticals Inc. regarding U.S. patent litigation over mirabegron (Myrbetriq). The agreement concludes all litigation between the two companies related to the product while settlement terms remain confidential. Litigation with other companies concerning mirabegron is ongoing. The company stated that the potential financial impact for the fiscal year ending March [----] is currently under review. AI impact ratingreference only: ★★☆☆☆ This is"
X Link 2026-02-12T17:24Z [----] followers, [---] engagements

"Beln Garijo to become Chief Executive Officer of Sanofi Sanofis Board of Directors decided not to renew Paul Hudsons mandate as Director. His last day as CEO will be February [--] [----]. Beln Garijo MD currently CEO of Merck KGaA has been appointed as the next Chief Executive Officer and will assume her duties following the Annual General Meeting on April [--] [----]. Olivier Charmeil will serve as Interim CEO during the transition. Garijo is expected to accelerate the execution of Sanofis strategy with a focus on strengthening R&D productivity governance and innovation capacity. Garijo previously"
X Link 2026-02-15T01:48Z [----] followers, [--] engagements

"BMSLife Science Cares ✔ Food is Health ✔ [---------] ✔ BMS500 #BMS #HealthEquity #FoodIsHealth #CSR"
X Link 2026-02-15T02:03Z [----] followers, [--] engagements

"AbbVieLove in Mind ✔ [--] ✔ [--] ✔ [--] #AbbVie #Migraine #LoveInMind # https://twitter.com/i/web/status/2022873641067909243 https://twitter.com/i/web/status/2022873641067909243"
X Link 2026-02-15T03:20Z [----] followers, [---] engagements

"AbbVie launched Love in Mind an educational initiative highlighting the emotional impact of migraine on romantic relationships. According to a Harris Poll survey of [---] U.S. adults living with migraine: 89% say its hard to feel present in a romantic relationship during an attack 51% have canceled or rescheduled dates due to migraine 78% have pushed through pain to maintain physical intimacy Country music star Jessie James Decker shared her personal experience living with migraine encouraging open conversations with healthcare providers to build personalized care plans. Migraine affects nearly"
X Link 2026-02-15T03:21Z [----] followers, [--] engagements

"CART BP pro24 Otsuka announced an agreement to obtain exclusive commercialization rights in Japan for the ring-type blood pressure monitor CART BP pro developed by South Koreas Sky Labs. AI Impact EvaluationReference: ★★★★☆ *This is an experimental index and is a reference value whose accuracy is not guaranteed. #BloodPressure #DigitalHealth #OtsukaPharmaceutical #SkyLabs #HealthTech #Wearable #Cardiology https://stellanews.life/medicalinformation/8845/ https://stellanews.life/medicalinformation/8845/"
X Link 2026-02-15T04:17Z [----] followers, [--] engagements

"BayerECR 2026MRIgadoquatrane360 Bayer to present new Phase III data for the investigational low-dose MRI contrast agent gadoquatrane at ECR [----] featuring a 60% reduction in gadolinium dose. AI ★★★★☆ #MRI #Radiology #Bayer #ECR2026 #Gadoquatrane #Phase3 #MedicalImaging #ContrastAgent https://stellanews.life/technology/8851/ https://stellanews.life/technology/8851/"
X Link 2026-02-15T10:46Z [----] followers, [--] engagements

"S&P Upgrades Teva to BB+ Moodys Revises Outlook to Positive Reflecting Strong Execution of Pivot to Growth Strategy 📊💊Teva Pharmaceutical Industries (NYSE/TASE: TEVA) announced that: 🔹 S&P Global Ratings upgraded its long-term issuer rating to BB+ (stable outlook) 🔹 Moodys affirmed its B1a rating and revised its outlook to positiveThe agencies cited Tevas: Consistent deleveraging with leverage expected to fall below 4.25x Revenue growth after five years of decline Strength in branded and biosimilar portfoliosCFO Eli Kalif noted the upgrades reflect Tevas disciplined execution and strong"
X Link 2025-12-31T15:27Z [----] followers, [--] engagements

"Santen Launches Verkazia in China for Severe Vernal Keratoconjunctivitis Expanding Pediatric Eye-Care Options 👁 Santen Pharmaceutical announced the launch of Verkazia (cyclosporine ophthalmic emulsion) in China for the treatment of severe vernal keratoconjunctivitis (VKC) in children and young adults aged [--] and older. 🔹 Immunosuppressive mechanism targeting T-cell activation via IL-2 inhibition 🔹 Preservative-free cationic emulsion formulation improves ocular surface delivery 🔹 Aims to reduce corneal damage and dependence on corticosteroids This launch broadens access to non-steroidal"
X Link 2025-12-31T16:18Z [----] followers, [--] engagements

"Tanabe Pharma Transfers Global Edaravone Business to Shionogi in $2.5B+ Rare Disease Deal 💊 Tanabe Pharma announced an agreement to transfer global rights of its edaravone (RADICAVA/Radicut) business used to treat amyotrophic lateral sclerosis (ALS) to Shionogi & Co. Ltd. 🔹 Transaction value: $2.5 billion upfront + sales-based royalties 🔹 Regions: Japan U.S. and other global markets 🔹 Completion expected in April [----] pending regulatory approvals 🔹 Existing supply chain to remain unchanged The deal reflects both companies strategic focus strengthening Shionogis rare disease portfolio"
X Link 2025-12-31T16:20Z [----] followers, [---] engagements

"Shionogi Receives Japanese Approval for Zuranolone (Zazubay) A Novel GABA-A Modulating Antidepressant 🧠💊Shionogi & Co. Ltd. announced the Japanese approval of zuranolone (brand name: Zazubay) for the treatment of major depressive disorder (MDD).🔹 Acts as a GABA-A receptor positive allosteric modulator (PAM) 🔹 Designed as a 14-day oral treatment for faster symptom improvement 🔹 Phase [--] trial showed significant improvement versus placebo 🔹 Tolerability reported as generally favorableZuranolone introduces a new mechanism distinct from conventional antidepressants aiming to address the"
X Link 2025-12-31T16:22Z [----] followers, [--] engagements

"Shionogi to Acquire Global RADICAVA Business from Tanabe Pharma in $2.5B Deal Strengthening Rare Disease Platform 💊 Shionogi & Co. Ltd. announced plans to acquire the global RADICAVA(edaravone) business including RADICAVA ORS and IV formulations via a newly established entity by Tanabe Pharma. 🔹 Transaction value: USD [---] billion upfront + potential sales-based royalties 🔹 Completion expected in April [----] 🔹 Adds approximately USD [---] million in annual global revenue 🔹 Strengthens commercial infrastructure in rare disease therapeutics The acquisition positions Shionogi for long-term"
X Link 2025-12-31T16:24Z [----] followers, [---] engagements

"Shionogi and Salubritas Partner to Develop Regenerative Therapies for Hearing Loss 👂🧬 Shionogi & Co. Ltd. announced joint R&D and investment agreements with Salubritas Therapeutics aiming to restore hearing through regeneration of sensory hair cells in the inner ear. 🔹 Focus: Drug discovery for hearing loss caused by hair cell damage 🔹 Scope: Joint research and investment framework 🔹 Stage: Agreement signing (no clinical data disclosed yet) The collaboration marks Shionogis entry into regenerative approaches for sensorineural hearing loss an area with few current treatment options beyond"
X Link 2025-12-31T16:26Z [----] followers, [---] engagements

"Onos Braftovi combination approved in South Korea for first-line BRAF-mutated colorectal cancer Ono Pharmaceutical announced regulatory approval for encorafenib (Braftovi) + cetuximab + FOLFOX as a first-line therapy for unresectable or recurrent BRAF-mutant metastatic colorectal cancer (mCRC). 📊 Based on the phase [--] BREAKWATER trial: ORR: 60.9% vs 40.0% (p=0.0008) Median PFS: [----] vs [---] months (HR=0.53 p0.0001) No new safety signals reported This marks an expansion of targeted therapy options for BRAF-mutant mCRC in Asia. 🔗 Read more: #OnoPharma #Braftovi #Encorafenib #Cetuximab #FOLFOX"
X Link 2026-01-13T19:33Z [----] followers, [--] engagements

"cUTI NMPA 🔹 🔹 🔹 🔹 AMR # # #Cefiderocol # # # # #AMR #NMPA #"
X Link 2026-01-13T19:43Z [----] followers, [---] engagements

"Shionogis cefiderocol approved in China for complicated urinary tract infections Chinas NMPA has approved cefiderocol for complicated urinary tract infections (cUTI) including pyelonephritis caused by Gram-negative bacteria. 📊 Based on: International multicenter and China double-blind studies Non-inferiority vs imipenem/cilastatin confirmed No new safety concerns observed The approval provides a new treatment option amid rising antimicrobial resistance (AMR). 🔗 Read more: #Shionogi #Cefiderocol #cUTI #AMR #AntimicrobialResistance #InfectiousDiseases #China #NMPA #Antibiotic #Pyelonephritis"
X Link 2026-01-13T19:44Z [----] followers, [--] engagements

"Eli LillyVentyx Biosciences12 Lilly Ventyx Biosciences 💡 [-----] NLRP3 [----] Lilly #EliLilly #VentyxBiosciences #NLRP3 #Inflammation #SmallMolecule #Autoimmune #Cardiometabolic # # https://twitter.com/i/web/status/2011183422996435294 https://twitter.com/i/web/status/2011183422996435294"
X Link 2026-01-13T21:07Z [----] followers, [--] engagements

"Eli Lilly to acquire Ventyx Biosciences for $1.2B expanding its oral small-molecule portfolio in inflammatory diseases 🔬 All-cash deal at $14/share expected to close 1H [----] Adds NLRP3 inhibitors and other oral immunology assets Targets cardiometabolic neurodegenerative & autoimmune conditions Strengthens Lillys inflammation and immunology R&D platform 🔗 Read more: #Lilly #Ventyx #NLRP3 #Inflammation #Immunology #SmallMolecule #BiotechAcquisition #DrugDiscovery #Rheumatology https://stellanews.life/technology/8614/ https://twitter.com/i/web/status/2011183545512050872"
X Link 2026-01-13T21:08Z [----] followers, [--] engagements

"AMR ✔ [--] ✔ AMR ✔ WHO26135 AMR # # #"
X Link 2026-01-21T20:09Z [----] followers, [--] engagements

"Shionogi Receives MHLW Ministers Award for Cefiderocol in AMR Strategy at the 8th Japan Medical R&D Grand Prize Shionogi has been awarded the Minister of Health Labour and Welfare Prize at the 8th Japan Medical Research and Development Grand Prize for its contribution to combating antimicrobial resistance (AMR) through the development of cefiderocol a siderophore cephalosporin antibiotic. As of April [----] cefiderocol had been approved in [--] countries or regions and is part of global access initiatives in [---] countries through partnerships with GARDP and CHAI. It is also included on the WHOs"
X Link 2026-01-21T20:10Z [----] followers, [--] engagements

"ViiV21.7 ✔ Pfizer21.7 ✔ GSK78.3 ✔ HIV GSKPfizer3HIVViiV HealthcarePfizer11.7GSK220261 # #HIV #"
X Link 2026-01-21T20:12Z [----] followers, [----] engagements

"GSK Pfizer and Shionogi Restructure Shareholding in ViiV Healthcare; Shionogis Stake Increases to 21.7% GSK Pfizer and Shionogi have agreed to restructure the shareholding of ViiV Healthcare a company specializing in HIV treatment and prevention. Under the agreement: Pfizer will divest its 11.7% stake in ViiV Healthcare Shionogis stake will increase from 10% to 21.7% GSK will retain its 78.3% majority ownership This restructuring is intended to simplify the shareholder structure and reinforce long-term R&D collaboration in HIV therapeutics. The transaction is expected to close in Q1 2026"
X Link 2026-01-21T20:12Z [----] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing